compname posts q4 2021 results.
q1 kidney results were in line with expectations; same facility is trending at the low end of previous guidance.
sees fy revenue $6.6 billion.
not expects fy non-gaap sales up 3.5% to 4.5%.
q4 adjusted operating income per share $380.0.
compname posts q4 non-gaap operating loss per share $0.48.
Paraphrase: Let me elaborate on each and everything related to each
q1 adjusted earnings per share $0.51.
compname reports second quarter 2021 results, sees some additional upside impact from covid-19; sees some swing factors in 2019.
q1 earnings per share $2.17.
q4 revenue guidance increased 4 percent.
q1 adjusted earnings per share $1.00.
anticipate clinical teammate wages are going to continue to increase due to higher costs for covid-19 labor costs.
compname posts qtrly loss per share.
operating trends in segments were negatively impacted by decreased pricing on organic and external volume, resulting in an approximate 3% decrease in quarterly operating income.
q1 revenue $0.49 billion.
